Slideshow
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
This slideshow examines cabozantinib (Cabometyx), indicated for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.